Familial Mediterranean fever: clinical, molecular and management advancements.

Familial Mediterranean fever: clinical, molecular and management advancements. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Familial Mediterranean fever: clinical, molecular and management advancements. Abstract Text:

M Lidar,A Livneh,M Lidar,A Livneh,

Familial Mediterranean fever (FMF), the most frequent of the periodic fever syndromes, is an autosomal recessive disease, predominantly affecting people of Mediterranean descent. The disease is caused by mutations in the MEFV gene, encoding the pyrin protein thought to be associated with the interleukin-1 related inflammation cascade. The condition manifests as attacks of serositis, commonly involving the abdomen, chest or joints, typically accompanied by fever and elevated acute phase reactants. Attacks subside spontaneously within one to three days, without residue. Continuous treatment with colchicine, at a daily dose of 1 to 2 mg, reduces attack frequency, duration and intensity in the majority of patients, and also prevents the development of secondary amyloidosis, the most dreaded complication of the disease. In this communication we review the current state of the art in the diagnosis and care of FMF patients, starting with the presentation of a typical case.

Familial Mediterranean fever: clinical, molecular and management advancements. Publishing Authors By Initials

M Lidar,A Livneh,M Lidar,A Livneh,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Familial Mediterranean fever: clinical, molecular and management advancements. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The Netherlands journal of medicine

VOLUME: 65

Page Numbers: 318-24

Journal Abbreviation:

ISSN: 0300-2977

DAY: 23

MONTH: Oct

YEAR: 2007

Familial Mediterranean fever: clinical, molecular and management advancements. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 356133

Familial Mediterranean fever: clinical, molecular and management advancements. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Familial Mediterranean fever: clinical, molecular and management advancements. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Familial Mediterranean fever: clinical, molecular and management advancements.

AFFILIATION: Heller Institute of Medical Research, Sheba Medical Centre, Tel-Hashomer, affiliated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. merav.lidar@sheba.health.gov.il

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Neth J Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Familial Mediterranean fever: clinical, molecular and management advancements Related Publications

• Analysis of strand transfer and template switching mechanisms of DNA gap repair by homologous recombination in Escherichiacoli: predominance of strand transfer.
• Appendectomy in familial Mediterranean fever: clinical, genetic and pathological findings.
• Biochemical analysis of UV mutagenesis in Escherichia coli by using a cell-free reaction coupled to a bioassay: identification of a DNA repair-dependent, replication-independent pathway.
• DNA repair of oxidative DNA damage in human carcinogenesis: Potential application for cancer risk assessment and prevention.
• Familial Mediterranean fever and cryptogenic cirrhosis.
• Familial Mediterranean fever gene and protection against asthma.
• Familial Mediterranean fever: clinical, molecular and management advancements.
• Interferon-alpha as a Treatment Modality for Colchicine- Resistant Familial Mediterranean Fever.
• MEFV mutations and palindromic rheumatism: Comment on the article by Cañete et al.
• Mutations in the familial Mediterranean fever gene of patients with IgA nephropathy and other forms of glomerulonephritis.
• PKCeta expression contributes to the resistance of Hodgkin's lymphoma cell lines to apoptosis.
• Reduced efficiency and increased mutagenicity of translesion DNA synthesis across a TT cyclobutane pyrimidine dimer, but not a TT 6-4 photoproduct, in human cells lacking DNA polymerase eta.
• Reduced repair of the oxidative 8-oxoguanine DNA damage and risk of head and neck cancer.
• Single-stranded DNA-binding Protein Recruits DNA Polymerase V to Primer Termini on RecA-coated DNA.
• Unique spectrum of MEFV mutations in Iranian Jewish FMF patients--clinical and demographic significance.
• [Aspirin and endoscopy]
• [ECG changes during stroke]
• [Neurogenic pulmonary edema]